| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |
Abstract |
|---|
|
|
|---|
Myosin light chain phosphorylation results in cellular contraction and is a critical component of agonist-mediated endothelial cell (EC) junctional gap formation and permeability. We have shown that this reaction is catalyzed by a novel high molecular-weight Ca2+/calmodulin-dependent nonmuscle myosin light chain kinase (MLCK) isoform recently cloned in human endothelium (Am. J. Respir. Cell Mol. Biol., 1997;16:489-494). To characterize EC MLCK expression further in cultured and adult tissues, we employed immunoblotting techniques and reverse transcriptase-polymerase chain reaction to demonstrate that freshly isolated and cultured human macro- and microvascular EC express only the EC MLCK isoform (214 kD), which is distinct from smooth-muscle MLCK isoforms (130 to 150 kD). Immunocytochemical studies demonstrated the presence of the high molecular-weight MLCK isoform in adult human cardiac endothelium using anti-MLCK antibodies, which preferentially recognize the high molecular-weight EC MLCK isoform. Monitoring of MLCK expression in different cell types with antibodies generated against a unique human EC MLCK N-terminal sequence revealed a high level of expression of the 214-kD enzyme in endothelium, minimal level of expression in smooth muscle, and no expression in skeletal muscle. These data suggest that the novel 214-kD kinase, the only MLCK isoform found in endothelium, may be preferentially expressed in this nonmuscle tissue.
| |
Introduction |
|---|
|
|
|---|
A key vascular endothelial cell (EC) function is to serve as
a semiselective barrier between circulating blood and the
interstitial fluid. Agonist-induced EC activation is tightly
linked to the disruption of EC monolayer integrity, an increase in vascular permeability, and ultimately organ dysfunction. Although increased vascular EC permeability is
a cardinal feature of inflammation and thrombotic processes, the biochemical basis for regulating this important
vascular response remains poorly understood. Early studies by Majno and Palade (1) determined that a breach in the integrity of the EC monolayer induced by bioactive
agents involves the formation of intercellular gaps, a morphologic change mechanistically linked to interstitial edema.
Majno and colleagues (2) observed that the nucleus and
cytoplasm of stimulated EC undergo changes characteristic of contraction including fibrillar band formation at regular intervals. Confluent EC form specific microfilamentous
structures ("dense peripheral bands"), including
-actin,
myosin, and tropomyosin, that colocalize with F-actin (3).
EC activation evoked by the serine protease thrombin
results in significant alterations in F-actin filament distribution, loss of dense peripheral bands, an increase in
the number of cytoplasmic stress fibers (4), and isometric
force development (5), providing significant cellular shape
changes and dramatic increases in EC monolayer permeability (6). In well-developed smooth-muscle (SM) model
systems, contraction is initiated by an increase in cytosolic
free Ca2+ that associates with calmodulin (CaM) to activate the Ca2+/CaM-dependent myosin light chain kinase
(MLCK). This increase in myosin light chain (MLC) phosphorylation results in activation of Mg2+-adenosine triphosphatase actomyosin activity and finally force generation (7). In EC, centripetal tension generation appears to
be similarly driven by an actomyosin molecular motor tightly linked to MLC phosphorylation catalyzed by a Ca2+/CaM-dependent MLCK (5, 8, 9). Reductions in cytosolic Ca2+i
or inhibition of MLCK enzymatic activity results in loss of isometric tension and marked attenuation of thrombin-stimulated EC gap formation and barrier dysfunction (5,
8). These data indicate that SM and nonmuscle cells such
as EC share similar contractile machinery in which MLCK-catalyzed MLC phosphorylation is a key event (5, 8, 9, 11,
12). Activity of EC MLCK is a central determinant of
basal and agonist-mediated permeability properties (8).
Despite numerous similarities between EC and SM contractile processes, distinct differences exist in the specific cytoskeletal and regulatory proteins involved in contractile events. Specific observations that illustrate distinct contractile regulation by EC and SM cells include: (1) unlike SM, increases in Ca2+ in EC are necessary but insufficient to increase EC MLC phosphorylation (8, 13); (2) unlike SM, two Ser/Thr phosphatases (types 1 and 2B) are involved in agonist-induced MLC dephosphorylation in endothelium (14); and (3) whereas the phosphorylation of calponin (a CaM-, actin-, and Ca2+-binding protein) is an important regulatory event in SM contraction, immunoreactive calponin is absent in both human and bovine EC (W. T. Gerthoffer and J. G. Garcia, unpublished observations). Recently, we have identified a novel high molecular-weight non-muscle MLCK isoform (214 kD) in cultured endothelium that is unique and distinct from its SM MLCK counterpart (130 to 150 kD). Molecular cloning of this enzyme from human endothelium identified an 8.1-kb complementary DNA (cDNA) with substantial homology (> 95%) to the coding region of the rabbit and bovine SM MLCK in amino acids #923-1914 (15). Sequence analysis also identified, however, a 5' stretch of novel sequence (amino acids #1-922) that is not contained in the open reading frame of mammalian SM MLCK (16). Given the important role of EC MLCK in the regulation of EC barrier properties, in this report we have further characterized the expression of this novel EC MLCK isoform in several adult and cultured EC tissues. Our data suggest that the EC MLCK isoform may represent a novel nonmuscle MLCK isotype that is preferentially expressed in endothelium.
| |
Materials and Methods |
|---|
|
|
|---|
Reagents
Endothelial cell cultures were maintained in M-199 or DME media (GIBCO, Chagrin Falls, OH) supplemented with 20% (vol/vol) colostrum-free bovine serum (Irvine Scientific, Santa Ana, CA), 1% antibiotic and antimycotic (penicillin, 10,000 units/ml; streptomycin, 10 mg/ml; and amphotericin B, 25 µg/ml) (K.C. Biologicals, Lenexa, KS), and 0.1 mM nonessential amino acids (GIBCO). Unless specified, reagents were obtained from Sigma Chemical Company (St. Louis, MO). Phosphate-buffered saline (PBS) and Hanks' balanced salt solution without phenol red were purchased from GIBCO (Grand Island, NY).
Preparation of Human and Bovine Endothelial Cells
Human umbilical vein EC (HUVEC) were isolated from umbilical cords as previously described (17, 18) by treatment with collagenase (0.1%) to detach the endothelium. The cells were plated onto gelatin-coated 25-cm2 flasks and cultured with M199 medium containing 20% colostrum-free bovine serum (Sigma), heparin (2 U/ml), endothelial cell growth factor (30 µg/ml; UBI, Lake Placid, NY), and antibiotics. Confluent cells were propagated twice by detachment with 1 ml trypsin/ethylenediaminetetraacetic acid (EDTA) (0.05%/0.02%) for 1 to 2 min at 25°C and replating. The purity of the cells was confirmed by the typical cobblestone morphology judged routinely by light microscopy and by the presence of von Willebrand factor as assessed by immunofluorescence microscopy. Human dermal microvascular EC (HDMVC) (CC-2505; Clonetics Corp., San Diego, CA) were obtained frozen at passage 3-4 and cultured 2 to 3 additional passages with microvascular endothelial cell growth media (CC-3125; Clonetics).
Bovine pulmonary artery endothelial cells (BPAEC)
were obtained from the main pulmonary artery, secondary branches were immediately dissected en bloc from
heart/lung/trachea preparations at the slaughterhouse and
packed in ice-cold saline. The lumen of the vessel was
carefully exposed by longitudinal slicing and the endothelium was removed by gentle scraping with minimal fibroblast and SM cell contamination. The cells were frozen
and stored at
70°C. A small sample of the freshly isolated cells was plated and grown to confluent monolayers
to demonstrate their purity by phase-contrast microscopy
and staining for von Willebrand factor antigen. For routine studies of cultured BPAEC, cells (CCL-209) were obtained as cryopreserved cells at the sixteenth passage from
American Type Culture Collection (Rockville, MD) and
cultured as previously described (6) using complete medium (DMEM) with 10 µg/ml endothelial cell growth supplement (UBI) and 20% colostrum-free bovine calf serum
(Sigma). Cells were used from passages 19-24 and were
plated onto 100-cm2 dishes.
Bovine aortic endothelial cells (BAEC) were obtained from the aorta dissected en bloc from the heart/lung/trachea preparation as described for BPAEC. Bovine lung microvascular endothelial cells (BMVC) were a kind gift from Dr. Peter Del Vecchio (Albany Medical College, Albany, NY) at passage 11. The microvascular cells were passaged and cultured as previously described (13) and were propagated only three times. Bovine aortic smooth muscle cells (BASMC) were obtained by the explant technique from fresh cow aorta as described (19), cultured in DMEM with 10% serum and antibiotics, and used during passages 2-6.
Preparation of Specific Bovine and Rat Tissues
Bovine tracheal SM strips were dissected from the noncartilaginous muscle span between the cartilaginous rings of
the bovine trachea obtained from en bloc bovine heart/
lung/trachea preparations. Visible adipose and connective
tissue were carefully removed to improve purity and 3-mm
cubes of SM were snap-frozen in liquid nitrogen and
stored at
70°C. Lung samples, obtained from bovine lung, were sectioned into 3-mm cubes and snap-frozen in
liquid nitrogen. Skeletal muscle samples from the gastrocnemius muscle of an adult rat were sectioned into 3-mm
cubes, and cubes selected with minimal connective and
vascular tissue were frozen at
70°C. The inner epithelial
lining and glandular tissue was removed from samples of
stomach from an adult rat, and 3-mm cubes of smooth muscle were frozen for later analysis.
Western Immunoblotting
Proteins were extracted from cultured and freshly isolated EC and SM cell preparations using sodium dodecyl sulfate (SDS) sample buffer as previously described (20). Extracts were separated by 4 to 15%-gradient SDS-polyacrylamide gel electrophoresis (PAGE) (Bio-Rad, Hercules, CA), transferred to nitrocellulose (30 V overnight or 100 V for 2 h), and reacted with MLCK-specific antibodies as previously described (14, 21). Immunoreactive proteins were detected using an enhanced chemiluminescent detection system according to the manufacturer's directions (Amersham, Little Chalfont, Buckinghamshire, UK). For normalization of protein loading, tissue or cell extracts were initially subjected to SDS-PAGE and stained with Coomassie, and the relative amount of protein loaded in each lane was quantitated by densitometry on GS-670 Imaging densitometer (Bio-Rad). To obtain an equal amount of proteins for each probe, the sample volume was adjusted with SDS sample buffer and normalized proteins were subjected to Western immunoblotting. As noted in Table 1, four antibodies recognizing MLCK were used to study EC MLCK expression. Monoclonal antibody K36 (Sigma) was produced against purified chicken gizzard SM MLCK and recognizes SM MLCK from mammalian and avian species. Polyclonal antibody (D119), a generous gift from Dr. P. Gallagher (Indiana University, Indianapolis, IN) was produced in rabbits against a peptide representing the 12 amino acid repeat sequence (KPVGNAKPAETL) between amino acid residues #102-293 in the rabbit and bovine SM MLCKs (15, 22). Polyclonal antibody (V368) was raised in rabbits against a synthetic peptide corresponding to residues #368-374 of the newly cloned human EC MLCK (15). Polyclonal antibody raised in rabbits against highly conserved, independently expressed C-terminal fragment of SM MLCK known as kinase-related protein (KRP, or telokin) was a generous gift from Dr. D. M. Watterson (Northwestern University, Chicago, IL).
|
MLCK Immunoprecipitation under Denaturing Conditions
For immunoprecipitation, confluent EC monolayers in 60-mm tissue culture dishes were rinsed twice with 2 ml medium, further rinsed with 2 ml PBS, and scraped into 100 µl SDS/denaturing stop solution (PBS, pH 7.4; 1 mM EDTA;
1 mM ethyleneglycol-bis-(
-aminoethyl ether)-N,N'-tetraacetic acid; 50 mM NaF; 10 mM NaPP; 0.2 mM orthovanadate; 1% SDS; and 14 mM
-mercaptoethanol). The homogenate was prepared by passing the cell suspension
several times through a 16-gauge needle. Homogenates
were heat-treated at 110°C for 5 min, diluted 1:10 with 900 µl PBS and incubated with 50 µl of 10% Pansorbin suspension containing formalin-hardened and heat-killed Cowan 1 strain Staphylococcus aureus cells (Calbiochem, La Jolla,
CA) for 30 min at room temperature. Samples were clarified by microcentrifugation (Eppendorf, 5 min) and supernatants were incubated with 10 µl anti-MLCK antibodies
(60 min at room temperature or overnight at 4°C), then
with 50 µl of 10% Pansorbin suspension for 60 min at
room temperature. Immunocomplexes were pelleted by
microcentrifugation for 5 min, washed three times in 1 ml
PBS, boiled in 100 µl of SDS sample buffer (20) for 5 min,
separated from Pansorbin by microcentrifugation, and
subjected to SDS electrophoresis (20). After electrophoresis, proteins were transferred to nitrocellulose membranes
(21) and signals were detected by immunostaining with anti-MLCK antibodies.
Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)
Total RNA from HDMVC, adult BAEC, and BPAEC were extracted using guanidine isothiocyanate and CsCl2 centrifugation according to Sambrook and coworkers (23). Approximately 1 µg of total RNA was reverse transcribed using Superscript II (GIBCO BRL, Gaithersburg, MD). The synthesized first-strand cDNAs were subjected to PCR amplification using oligonucleotide primers that flank base pairs 2781-2174. PCR amplifications were performed using 1.5 mM MgCl2, 200 µM dNTP, and 1.25 units taq polymerase (Boehringer Mannheim, Indianapolis, IN) on Perkin-Elmer PCR Model 9600 (Perkin-Elmer, Foster City, CA). The cycle conditions include 94°C for 30 min, 60°C for 30 min, and 72°C for 1 min for 35 cycles.
Immunohistochemical Analysis
Immunocytochemical localization of MLCK was assessed
in normal and transplanted human cardiac tissues with the
D119 polyclonal MLCK antibody. Right ventricular endomyocardial biopsies from two donor hearts obtained before transplantation and from two cardiac allografts obtained 7 d and 3 yr after transplantation were embedded
in Optimum Cutting Temperature medium compound
(Miles Co., Elkhart, IN), snap-frozen in liquid nitrogen,
and stored at
20°C. Tissues were sectioned (4 µm) on a
Tissue-Tek cryostat (Miles), removed from the cryostat
blade by flash condensation onto glass microscope slides,
and air-dried at room temperature. The sections were
washed in 10 mM PBS, incubated 30 min at room temperature with D119 antibody (1:100), washed three times in PBS, and incubated 30 min with fluorescein isothiocyanate-conjugated goat F(ab')2 antirabbit antibody (Biomeda,
Foster City, CA). To confirm the spatial localization of
MLCK within the microcirculation, double antibody experiments (24, 25) with monoclonal antibodies to SM-specific
-actin (IA4; BioMaker, Rehovot, Israel) to localize vascular SM cells or with PECAM-1 (CD31; Dako, Santa
Barbara, CA) to localize EC (25, 26) were performed.
Mouse monoclonal antibodies were followed by rhodamine-conjugated goat F(ab')2 antimouse antibody (Protos Immunoresearch, San Francisco, CA). Control experiments
were performed by exposing tissue sections to PBS, to secondary antibodies only, or to irrelevant isotype-matched primary antibodies. The sections were coverslipped with aqueous mounting media and examined with a Leitz microscope
equipped for epifluorescence N2.1-type rhodamine and type
A fluoroblue interference filters. Single- and double-exposure photomicrographs were taken by using a Leitz camera and 35-mm Ektachrome film (ASA 200).
| |
Results |
|---|
|
|
|---|
Expression of MLCK in Cultured Human and Bovine Endothelium
We have recently reported the cloning of a novel high molecular-weight MLCK isoform from a HUVEC library with an apparent molecular weight on SDS-PAGE of 214 kD (15). Although the EC MLCK isoform is clearly distinct from the SM MLCK isoform (130 to 150 kD) (15), as depicted in Figure 1, our initial studies demonstrated that EC MLCK contains all regional motifs previously reported in SM MLCK (16), including the putative actin-binding domain (AA #923-964), MLC-binding region, catalytic core region, CaM-binding region, and the C-terminal region corresponding to the sequence of the SM protein known as KRP or telokin. Unlike the SM MLCK isoform, however, N-terminal amino acids #1-922 from the deduced HUVEC MLCK sequence are not found in the reported SM MLCK structure and do represent the unique EC MLCK isoform protein sequence. Therefore, we hypothesized that HUVEC MLCK may represent a novel nonmuscle high molecular-weight MLCK isoform expressed in endothelium. To study species- and site-specific expression of the EC MLCK isoform we used a panel of antibodies of varying specificity (Table 1). We first used a monoclonal antibody (clone K36; Sigma) produced against purified chicken gizzard SM MLCK, and a polyclonal antibody (D119) directed against the repeated 12-amino-acid sequence downstream of the putative actin-binding region (AA #1-41) of rabbit SM MLCK (Figure 1). Our preliminary experiments and published data (15, 22) demonstrate that the K36 antibody preferentially recognizes SM MLCK, whereas D119 antiserum preferentially detects the high molecular-weight MLCK isoform. Figure 2 demonstrates that cultured HUVEC and BMVC express only the high molecular-weight MLCK isoform, whereas cultured BASMC appear to express both high and low molecular-weight MLCK isoforms. Consistent with these results, HUVEC freshly isolated from umbilical cords expressed only the high molecular-weight MLCK isoform (data not shown).
|
|
KRP is an independently expressed protein considered to be a marker for the SM phenotype (27). This sequence is also contained in the COOH terminus of SM MLCK and is highly conserved in the C-terminus of the EC MLCK with more than 90% homology with SM MLCK (15). When the expression of KRP was examined in cultured endothelium using specific anti-KRP antibodies (Figure 3), in contrast to SM, KRP was only weakly detected in EC. The reason for the reduced KRP expression in EC when compared with SM is not clear, but this reduction is likely due to variations in transcriptional regulation between the two tissues. However, we cannot exclude the possibility that the KRP antibody produced against purified SM KRP (Table 1) may not efficiently recognize KRP when expressed in endothelium.
|
Expression of MLCK in Freshly Isolated Adult Bovine Endothelium
To determine MLCK isoform expression in adult EC, we isolated EC from BPAEC and BAEC and analyzed SDS cell extracts by Western immunoblotting with K36 and D119 antibodies. Figure 4 demonstrates that freshly prepared EC from adult bovine tissues express the 214-kD high molecular-weight MLCK isoform. Densitometric quantitation of MLCK detected by Western blot analysis demonstrates similar level of expression of EC MLCK in both cultured and freshly isolated cells (Figure 4C), whereas expression of the SM MLCK isoform was not detected in either EC preparation.
|
Immunodetection of EC MLCK in Human, Bovine, and Rat Tissues
We next extended these biochemical observations by demonstrating that the 214-kD EC MLCK isoform is present in human endomyocardial biopsies from normal donor hearts (n = 2) and from patients who have undergone cardiac transplantation (n = 2). Immunohistochemical analysis of human endomyocardial biopsies with anti-MLCK D119 antibodies (seen as blue in Figure 5) reveals the presence of the kinase in capillary, venous, and arteriolar endothelium, but not in cardiac muscle tissues of normal hearts (Figure 5) or hearts from cardiac allograft recipients (data not shown). The localization of MLCK reactivity on endothelium was confirmed using the double-antibody technique with an antibody to the EC-specific monoclonal marker PECAM (CD31) (Figure 5).
|
To study specific expression of the high molecular-weight EC MLCK isoform in different cell types, we used antibodies (V368) designed against the novel N-terminus of this enzyme (Figure 1) for Western blotting analysis of cell lysates. Figure 6 demonstrates that V368 antibodies cross-react only with the 214-kD MLCK isoform but not with the lower molecular-weight MLCK isoforms in all cell types examined. Examination of bovine EC and bovine and rat tissues (Figure 6) revealed that the 214-kD protein was highly expressed in endothelium and lung (highly enriched in endothelium), had very low expression in rat stomach SM, and was not expressed in rat skeletal muscle. It is interesting to note that the V368 antibody (which is specific to the EC MLCK isoform) does not recognize any protein in the tracheal SM sample (Figure 6, panel B), whereas the D119 antibodies (which preferentially recognize nonmuscle MLCK in different tissues) have weak cross-reactivity with a ~ 208-kD protein band in the same sample (Figure 4, panel B). The appeared discrepancy between the results with two different MLCK antibodies may reflect the existence of two high molecular-weight MLCK isoforms differentially expressed in SM and endothelial cells. The specific EC MLCK antibody (V368) weakly cross-reacts with a 214-kD protein band in rat stomach SM (Figure 6, panel A), which may reflect the limited nonmuscle contamination of this sample. Collectively, the immunologic data presented in Table 2 indicate that both cultured and in situ adult bovine and human endothelium express only the unique high molecular-weight 214-kD MLCK isoform.
|
|
Structural Relationship between Bovine and Human EC MLCKs
To characterize the degree of structural similarity between the previously cloned human EC MLCK and the bovine 214-kD MLCK isoform, we used several MLCK antibodies directed against different SM and EC MLCK epitopes (Figure 1) to immunoprecipitate MLCK from BPAEC under denaturing conditions. Western blotting analysis of immunoprecipitates with D119 anti-MLCK antibodies (Figure 7A) demonstrated that each antibody was able to immunoprecipitate the 214-kD protein in bovine endothelium, confirming a high degree of similarity between bovine and human EC MLCK in at least several antigenic epitopes. We next used RT-PCR to examine the similarity of EC MLCK in human and bovine endothelium using oligonucleotide primers which flank base pairs #2174-2781. As expected, only one amplified ~ 0.6-kb product was found in human (Figure 7B) and bovine (Figure 7C) EC, verifying that adult bovine EC express a high molecular-weight MLCK isoform that is highly similar to the human EC MLCK isoform.
|
| |
Discussion |
|---|
|
|
|---|
To understand the regulation of EC MLCK by Ca2+/CaM and other regulatory elements, we have recently cloned and sequenced the novel, high molecular-weight MLCK isoform expressed in human endothelium (15). The deduced amino acid sequence between AA #923-1914 revealed substantial homology to bovine stomach SM MLCK (> 90%) and to rabbit uterine SM MLCK (> 85%). However, the much larger molecular mass and the unique 5' open reading frame sequence (AA #1-922) distinguishes the 214-kD EC MLCK from the SM kinase (15, 16). To characterize the EC MLCK isoform further, we examined its expression in different cell types and tissues using antibodies specific for SM and EC MLCK (Table 2). The 214-kD EC MLCK, but not the SM MLCK isoform, is detected in cultured micro- and macrovascular EC and, more importantly, in EC freshly isolated from adult tissues. Consistent with this observation, the nonmuscle high molecular-weight MLCK transcript was recently detected in adult liver (28). Examination of the expression of the 214-kD isoform with specific anti-EC MLCK antibodies revealed very low expression of this MLCK isoform in adult stomach SM, possibly reflecting nonmuscle contamination of this tissue sample with EC MLCK isoform expression completely absent in tracheal SM and skeletal muscle. Immunocytochemical studies further localized the EC MLCK isoform to endothelium from normal adult human hearts and human cardiac allografts but not in cardiac muscle. This pattern of expression is significantly different from the expression of the recently described 208-kD "embryonic" MLCK isoform, which appears to be preferentially expressed in undifferentiated embryonic cells and early embryonic tissues (22). The possibility continues to exist that the "embryonic" 208-kD MLCK isoform as well as the high molecular-weight nonmuscle MLCK isoform described by Fisher and Ikebe (28) are developmentally regulated in SM but not in nonmuscle tissues. It is worth noting that despite the similarity in the molecular weights, the embryonic 208-kD MLCK isoform appears to exhibit specific structural differences when compared with our recently cloned EC MLCK 214-kD isoform. For example, we have recently shown that anti-KRP antibodies recognize EC MLCK (15) but do not cross-react with the 208-kD embryonic MLCK isoform (22), suggesting structural differences in the C-terminal portions of these high molecular-weight MLCK isoforms. Our present data indicate that specific anti-EC MLCK V368 antibodies do not cross-react with the 208-kD MLCK isoform minimally present in adult tracheal smooth muscle (22), suggesting a structural difference in the N-termini of these isoforms. Consistent with these results, our recent observations indicate that the high molecular-weight MLCK from smooth muscles binds more avidly to the cytoskeleton than does EC MLCK (A. D. Verin and J. G. N. Garcia, unpublished data). Comparison of the 214-kD EC MLCK isoform with the recently revised nonmuscle avian fibroblast MLCK sequence (29, 30) revealed substantial homology in the C-terminal parts of the two molecules (amino acids #923- 1914), but much less homology between amino acids 1 through 922. For example, only 38% homology exists between the two isoforms in the region flanked by residues #200-500 (15). In contrast, comparison of the EC MLCK isoform present in both human and bovine EC, either by immunoreactivity or by RT-PCR analysis, fails to reveal significant structural differences in the EC MLCK from the two species.
Together, these data suggest that cultured and adult bovine and human endothelium express only the unique nonmuscle MLCK isoform which, despite significant homology, may be distinct from either the embryonic 208-kD MLCK isoforms or nonmuscle MLCK isoforms present in other cell types. We speculate that members of this family of nonmuscle MLCKs may exhibit distinct functional activities and regulatory properties. Further studies designed to examine the biochemical regulation of the unique EC MLCK isoform are under way.
| |
Footnotes |
|---|
Address correspondence to: Alexander D. Verin, Ph.D., Johns Hopkins Asthma and Allergy Center, Room 5A.42A, 5501 Hopkins Bayview Circle, Baltimore, MD 21224-6801.
(Received in original form August 12, 1997 and in revised form March 2, 1998).
Abbreviations: bovine aortic endothelial cells, BAEC; bovine aortic smooth muscle cells, BASMC; bovine lung microvascular endothelial cells, BMVC; bovine pulmonary artery endothelial cells, BPAEC; calmodulin, CaM; endothelial cell(s), EC; human dermal microvascular endothelial cells, HDMVC; human umbilical vein endothelial cells, HUVEC; kinase-related protein, KRP; myosin light chain, MLC; myosin light chain kinase, MLCK; reverse transcriptase-polymerase chain reaction, RT- PCR; sodium dodecyl sulfate-polyacrylamide gel electrophoresis, SDS-PAGE; smooth muscle, SM.Acknowledgments: This work was supported by grants from the National Heart, Lung, and Blood Institute (HL50533, HL57462, HL58064); the American Heart Association; and the Veterans' Administration Medical Research Service; and an award from the American Lung Association of Indiana. The authors gratefully acknowledge Clare Cook, Steven Durbin, D. R. Miller, and Lakshmi Natarajan for their superb technical assistance, and Rebecca Snyder for her expert secretarial assistance.
| |
References |
|---|
|
|
|---|
1.
Majno, G., and
G. Palade.
1961.
Studies on inflammation: I. Effect of histamine and serotonin on vascular permeability: an electron microscopic study.
J. Biophys. Biochem. Cytol.
11:
571-605
.
2.
Majno, G.,
S. M. Shea, and
M. Leventhal.
1969.
Endothelial contraction induced by histamine-type mediators: an electron microscopic study.
J. Cell
Biol.
42:
647-672
3.
Wong, M. K. K., and
A. I. Gotlieb.
1986.
Endothelial cell monolayer integrity: I. Characterization of dense peripheral band of microfilaments.
Arteriosclerosis
6:
212-219
4.
Phillips, P. G.,
H. Lum,
A. B. Malik, and
M. F. Tsan.
1989.
Phallacidin prevents thrombin-induced increases in endothelial permeability to albumin.
Am. J. Physiol.
257:
C562-C567
5. Goeckeler, Z. M., and R. B. Wysolmerski. 1995. Myosin light chain kinase-regulated endothelial cell contraction: the relationship between isometric tension, actin polymerization, and myosin phosphorylation. J. Cell Biol. 130: 622-635 .
6. Garcia, J. G. N., A. S. Birnboim, R. Bizios, P. J. Del Vecchio, J. W. Fenton, and A. B. Malik. 1986. Thrombin-induced increases in albumin clearance across cultured endothelial monolayers. J. Cell. Physiol 128: 96-104 [Medline].
7. Adelstein, R. S., M. D. Pato, and M. A. Conti. 1981. The role of phosphorylation in regulating contractile proteins. Adv. Cyclic Nucleo. Res 14: 361-373 .
8. Garcia, J. G. N., H. W. Davis, and C. E. Patterson. 1995. Regulation of endothelial cell myosin light chain phosphorylation: role in thrombin- induced barrier dysfunction. J. Cell. Physiol 163: 510-522 [Medline].
9.
Wysolmerski, R. B., and
D. Lagunoff.
1990.
Involvement of myosin light
chain kinase in endothelial cell retraction.
Proc. Natl. Acad. Sci. USA
87:
16-20
10. Garcia, J. G. N., C. E. Patterson, C. Bahler, J. Aschner, C. M. Hart, and D. E. English. 1993. Thrombin receptor activating peptides (TRAPs) induce Ca2+i mobilization, PGI2 synthesis, PDGF mRNA expression, and barrier dysfunction in vascular endothelium. J. Cell. Physiol 156: 541-549 [Medline].
11.
Wysolmerski, R. B., and
D. Lagunoff.
1991.
Regulation of permeabilized
endothelial cell retraction by myosin phosphorylation.
Am. J. Physiol
261:
C32-C40
12. Moy, A. B., S. S. Shasby, B. D. Scott, and D. M. Shasby. 1993. The effect of histamine and cyclic adenosine monophosphate on myosin light chain phosphorylation in human umbilical vein endothelial cells. J. Clin. Invest 92: 1198-1206 .
13. Garcia, J. G. N., K. L. Schaphorst, C. M. Hart, S. Shi, A. D. Verin, K. Callahan, and C. E. Patterson. 1997. Mechanisms of ionomycin-induced endothelial cell barrier dysfunction. Am. J. Physiol. (Lung Cell Mol. Physiol.) 17: L172-L184 .
14. Verin, A. D., C. E. Patterson, M. A. Day, D. Lowery, and J. G. N. Garcia. 1995. Phosphatases (PPases) 1 and 2B regulate thrombin-induced endothelial cells (EC) contraction. FASEB J 9: 617A . (Abstr.) .
15. Garcia, J. G. N., V. Lazar, L. I. Gilbert-McClain, P. J. Gallagher, and A. D. Verin. 1997. Myosin light chain kinase in endothelium: molecular cloning and regulation. Am. J. Respir. Cell Mol. Biol. 16: 489-494 [Abstract].
16.
Gallagher, P. J.,
B. P. Herring,
S. A. Griffin, and
J. T. Stull.
1991.
Molecular
characterization of a mammalian smooth muscle myosin light chain kinase.
J. Biol. Chem
266:
23936-23944
17. Patterson, C. E., and J. G. N. Garcia. 1994. Regulation of thrombin-induced endothelial cell activation by bacterial toxins. Blood Coagul. Fibrinolysis 5: 63-72 [Medline].
18. Garcia, J. G. N., A. Azghani, K. S. Callahan, and A. R. Johnson. 1988. Effect of platelet activating factor on leukocyte-endothelial cell interactions. Thromb. Res 51: 83-96 [Medline].
19. Ma, S. F., J. G. N. Garcia, U. Reuning, S. P. Little, N. U. Bang, and E. P. Dixon. 1997. Thrombin induces thrombomodulin mRNA expression via the proteolytically activated thrombin receptor in cultured bovine smooth muscle cells. J. Lab. Clin. Med. 129: 611-619 [Medline].
20. Laemmli, U. K.. 1970. Cleavage of structural proteins during the assembly of head of bacteriophage. Nature 227: 680-685 [Medline].
21.
Towbin, H.,
T. Staehelin, and
J. Gordon.
1979.
Electrophoretic transfer of
proteins from polyacrylamide gels to nitrocellulose sheets: procedure and
some applications.
Proc. Natl. Acad. Sci. USA
76:
4350-4354
22.
Gallagher, P. J.,
J. G. N. Garcia, and
B. P. Herring.
1995.
Expression of a
novel myosin light chain kinase in embryonic tissues and cultured cells.
J.
Biol. Chem
270:
29090-29095
23. Sambrook, J., T. Fritsch, and T. Maniatis. 1989. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, New York.
24. Torry, D. S., V. J. Holt, J. A. Keenan, G. Harris, M. R. Caudle, and R. J. Torry. 1996. Vascular endothelial growth factor expression in cycling human endometrium. Fertil. Steril. 66: 72-80 [Medline].
25. Labarrere, C. A., and W. P. Faulk. 1994. Antigenic identification of cells in spiral artery trophoblastic invasion: validation of histological studies by triple antibody immunocytochemistry. Am. J. Obstet. Gynecol 171: 165-171 [Medline].
26.
Parums, D. V.,
J. L. Cordell,
K. Micklem,
A. R. Heryet,
K. C. Gatter, and
D. Y. Mason.
1990.
JC70: a new monoclonal antibody that detects vascular
endothelium associated antigen on routinely processed tissue sections.
J.
Clin. Pathol.
43:
752-757
27.
Gallagher, P. J., and
B. P. Herring.
1991.
The carboxyl terminus of the
smooth muscle myosin light chain kinase is expressed as an independent
protein, telokin.
J. Biol. Chem.
266:
23945-23952
28. Fisher, S. A., and M. Ikebe. 1995. Developmental and tissue distribution of expression of non-muscle and smooth muscle isoforms of myosin light chain kinase. Biochem. Biophys. Res. Commun 217: 696-703 [Medline].
29.
Shoemaker, M. O.,
W. Lau,
R. Shattuck,
A. Kwiatkowski,
P. E. Matrisian,
L. Guerra-Santos,
E. Wilson,
T. Lukas,
L. VanEldik, and
D. M. Watterson.
1990.
Use of DNA sequence and mutant analysis and antisense oligodeoxynucleotides to examine the molecular basis of nonmuscle myosin
light chain kinase autoinhibition, calmodulin recognition, and activity.
J.
Cell Biol
111:
1107-1125
30. Watterson, D. M., M. Collinge, T. J. Lukas, L. J. Van Eldik, K. G. Birukov, O. V. Stepanova, and V. P. Shirinsky. 1995. Multiple gene products are produced from a novel protein kinase transcription region. FEBS Lett. 373: 217-220 [Medline].
This article has been cited by other articles:
![]() |
C. Csortos, I. Kolosova, and A. D. Verin Regulation of vascular endothelial cell barrier function and cytoskeleton structure by protein phosphatases of the PPP family Am J Physiol Lung Cell Mol Physiol, October 1, 2007; 293(4): L843 - L854. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Ohlmann, A. Tesse, C. Loichot, H. R. Ranaivo, G. Roul, C. Philippe, D. M. Watterson, J. Haiech, and R. Andriantsitohaina Deletion of MLCK210 induces subtle changes in vascular reactivity but does not affect cardiac function Am J Physiol Heart Circ Physiol, December 1, 2005; 289(6): H2342 - H2349. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. M. Goeckeler and R. B. Wysolmerski Myosin Phosphatase and Cofilin Mediate cAMP/cAMP-dependent Protein Kinase-induced Decline in Endothelial Cell Isometric Tension and Myosin II Regulatory Light Chain Phosphorylation J. Biol. Chem., September 23, 2005; 280(38): 33083 - 33095. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. Clayburgh, S. Rosen, E. D. Witkowski, F. Wang, S. Blair, S. Dudek, J. G. N. Garcia, J. C. Alverdy, and J. R. Turner A Differentiation-dependent Splice Variant of Myosin Light Chain Kinase, MLCK1, Regulates Epithelial Tight Junction Permeability J. Biol. Chem., December 31, 2004; 279(53): 55506 - 55513. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Mehta, J. Bhattacharya, M. A. Matthay, and A. B. Malik Integrated control of lung fluid balance Am J Physiol Lung Cell Mol Physiol, December 1, 2004; 287(6): L1081 - L1090. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Pellegrino, E. Furmaniak-Kazmierczak, J. C. LeBlanc, T. Cho, K. Cao, S. M. Marcovina, M. B. Boffa, G. P. Cote, and M. L. Koschinsky The Apolipoprotein(a) Component of Lipoprotein(a) Stimulates Actin Stress Fiber Formation and Loss of Cell-Cell Contact in Cultured Endothelial Cells J. Biol. Chem., February 20, 2004; 279(8): 6526 - 6533. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. P. SOMLYO and A. V. SOMLYO Ca2+ Sensitivity of Smooth Muscle and Nonmuscle Myosin II: Modulated by G Proteins, Kinases, and Myosin Phosphatase Physiol Rev, October 1, 2003; 83(4): 1325 - 1358. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. K. McFawn, L. Shen, S. G. Vincent, A. Mak, J. E. Van Eyk, and J. T. Fisher Calcium-independent contraction and sensitization of airway smooth muscle by p21-activated protein kinase Am J Physiol Lung Cell Mol Physiol, May 1, 2003; 284(5): L863 - L870. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. PETRACHE, K. BIRUKOV, A. L. ZAIMAN, M. T. CROW, H. DENG, R. WADGAONKAR, L. H. ROMER, and J. G. N. GARCIA Caspase-dependent cleavage of myosin light chain kinase (MLCK) is involved in TNF-{alpha}-mediated bovine pulmonary endothelial cell apoptosis FASEB J, March 1, 2003; 17(3): 407 - 416. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Kanthou and G. M. Tozer The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells Blood, March 15, 2002; 99(6): 2060 - 2069. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Stevens, R. Rosenberg, W. Aird, T. Quertermous, F. L. Johnson, J. G. N. Garcia, R. P. Hebbel, R. M. Tuder, and S. Garfinkel NHLBI workshop report: endothelial cell phenotypes in heart, lung, and blood diseases Am J Physiol Cell Physiol, November 1, 2001; 281(5): C1422 - C1433. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Dudek and J. G. N. Garcia Cytoskeletal regulation of pulmonary vascular permeability J Appl Physiol, October 1, 2001; 91(4): 1487 - 1500. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Nilius and G. Droogmans Ion Channels and Their Functional Role in Vascular Endothelium Physiol Rev, October 1, 2001; 81(4): 1415 - 1459. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Petrache, A. D. Verin, M. T. Crow, A. Birukova, F. Liu, and J. G. N. Garcia Differential effect of MLC kinase in TNF-{alpha}-induced endothelial cell apoptosis and barrier dysfunction Am J Physiol Lung Cell Mol Physiol, June 1, 2001; 280(6): L1168 - L1178. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Norwood, T. M. Moore, D. A. Dean, R. Bhattacharjee, M. Li, and T. Stevens Store-operated calcium entry and increased endothelial cell permeability Am J Physiol Lung Cell Mol Physiol, November 1, 2000; 279(5): L815 - L824. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Stevens, J. G. N. Garcia, D. M. Shasby, J. Bhattacharya, and A. B. Malik Mechanisms regulating endothelial cell barrier function Am J Physiol Lung Cell Mol Physiol, September 1, 2000; 279(3): L419 - L422. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Shi, J. G. N. Garcia, S. Roy, N. L. Parinandi, and V. Natarajan Involvement of c-Src in diperoxovanadate-induced endothelial cell barrier dysfunction Am J Physiol Lung Cell Mol Physiol, September 1, 2000; 279(3): L441 - L451. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. AMMIT, C. L. ARMOUR, and J. L. BLACK Smooth-Muscle Myosin Light-Chain Kinase Content Is Increased in Human Sensitized Airways Am. J. Respir. Crit. Care Med., January 1, 2000; 161(1): 257 - 263. [Abstract] [Full Text] |
||||
![]() |
J. G. N. Garcia, A. D. Verin, K. Schaphorst, R. Siddiqui, C. E. Patterson, C. Csortos, and V. Natarajan Regulation of endothelial cell myosin light chain kinase by Rho, cortactin, and p60src Am J Physiol Lung Cell Mol Physiol, June 1, 1999; 276(6): L989 - L998. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. D. Verin, L. I. Gilbert-McClain, C. E. Patterson, and J. G. N. Garcia Biochemical Regulation of the Nonmuscle Myosin Light Chain Kinase Isoform in Bovine Endothelium Am. J. Respir. Cell Mol. Biol., November 1, 1998; 19(5): 767 - 776. [Abstract] [Full Text] |
||||
![]() |
K. G. Birukov, C. Csortos, L. Marzilli, S. Dudek, S.-F. Ma, A. R. Bresnick, A. D. Verin, R. J. Cotter, and J. G. N. Garcia Differential Regulation of Alternatively Spliced Endothelial Cell Myosin Light Chain Kinase Isoforms by p60Src J. Biol. Chem., March 9, 2001; 276(11): 8567 - 8573. |